Biosimilars

The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.

Latest News

Retinal condition  | Image Credit: Yakobchuk Olena - stock.adobe.com
Biosimilar Aflibercept P041 as Effective, Safe as Originator in nAMD

October 30th 2024

Biosimilar aflibercept (P041) demonstrated comparable safety and efficacy to the originator aflibercept (Eylea) in treating patients with retinal conditions like neovascular age-related macular degeneration (nAMD).

health policy chart | Image credit: JOURNEY STUDIO7 - stock.adobe.com
Exploring the Complexities of Biosimilars and Interchangeability

October 30th 2024

Cost of health care  | Image Credit: Scott Hales - stock.adobe.com
Biosimilars Expand Access and Reduce Costs in Oncology, Immunology

October 28th 2024

Market share increase | Image Credit: Kiattisak - stock.adobe.com
Samsung Bioepis Reports 2024 Biosimilar Market Growth Trends

October 15th 2024

FDA approve graphic on screen over a doctor | Image credit: wladimir1804 - stock.adobe.com
FDA Approves Imuldosa, a Fifth Biosimilar to Stelara

October 11th 2024

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo